Nippon Shinyaku and Roche Terminate NS-220 License Agreement.Tokyo Tokyo (tō`kēō), city (1990 pop. 8,163,573), capital of Japan and of Tokyo prefecture, E central Honshu, at the head of Tokyo Bay. , Japan, Dec 18, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Nippon Nippon (nĭp`ŏn, nĭpŏn`), name for Japan, derived from Dai Nippon, meaning Great Japan. The expression comes from the Chinese ideograph for the place where the sun comes from, or Land of the Rising Sun. Shinyaku Co., Ltd. announced on December 15, 2007 that Roche will terminate the License Agreement on Nippon Shinyaku's new investigational drug, NS-220, for the treatment of dyslipidemia dyslipidemia /dys·lip·id·e·mia/ (-lip?id-e´me-ah) abnormality in, or abnormal amounts of, lipids and lipoproteins in the blood. dys·lip·i·de·mi·a n. . Roche's decision is based purely on a regular portfolio review and prioritization exercise that has just been completed across its pharmaceuticals division. NS-220 is a novel agent discovered by Nippon Shinyaku and was licensed out to Roche in September 2003. Roche has been conducting the Phase I studies in Europe from December 2004. The future strategy of NS-220 development, including search for a new development partner in and outside Japan, will be decided after reviewing the result of Phase I studies performed by Roche. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion